What are the latest content updates?

• Updates to images, text, and references throughout the section and contains details related to the latest WHO Classification of Tumours: Digestive System Tumours, which include a change in how appendiceal neoplasms are classified, among other things.
• Includes 10-15 new topics on a variety of topics, including new information on targeted gene therapies, genetic variants of gastric and colonic carcinoma and the genetic syndromes that lead to GI tract cancers, COVID-19’s effects on the GI tract, iatrogenic (drug-induced) gastrointestinal diseases, and more.
• Additional new content covers the changed approach to GI endocrine neoplasms and how to differentiate Grade 3 endocrine tumors from high-grade neuroendocrine carcinomas.
• Provides invaluable information for busy pathologists who need easy access to details on neoplastic and nonneoplastic gastrointestinal diseases of the digestive tract to make specific diagnoses and prepare accurate, informative GI pathology reports.
• Includes important new material on recently discovered genetic alterations in GI cancers and direct healing therapies for them, as well as a variety of new chapters on other timely issues, such as COVID-19’s effects on the GI system, drug-induced GI diseases, and more.

• Updates to 23 topics in the section including:
  • NUT Carcinoma: Made minor corrections to text, updated references, included information about cytology, and updated some of the management/treatment based on new studies that came out this year.
  • Adenoid Cystic Carcinoma: Text and references updated, included cytology description.
  • Castleman’s disease: Added additional points to the treatment consensus guidelines. Added references.
  • Lymphoblastic Lymphoma: Added numerous new references to this; added molecular information concerning KRAS, added term "mucinous cell clusters" and the possibility of developing into invasive mucinous adenocarcinoma. Added gross photograph of CPAM type I.
  • Primary Pulmonary Myxoid Sarcoma: Since most BST authors now consider PPMS to simply be a myxoid variant of angiomatoid fibrous histiocytoma; or at least on the spectrum with AFH, the topic has been updated to reflect that.
  • Synovial Sarcoma of Mediastinum: Added SSX/SS18 antibody images.

• The topic VEXAS Syndrome has been updated.

• Updates to Mpox with new references and text, including epidemiology (current mpox clade 1 outbreak), as well as adding a mention of borealpox/Alaskapox recently in the news due to the first fatal case.

• Detailed, up-to-date information on maternal COVID-19 and placental pathology, including SARS-CoV-2 placentitis, which is associated with stillbirth and fetal distress
• New topics on fetal hydrops, common placental associations with stillbirths, second trimester demise, and more
• Updates throughout to topics, images, and references to reflect the most current diagnoses and provide ease for daily case sign-out
• Easy-to-use details on gross and microscopic anatomy and physiology that enable readers to make diagnoses with clinical implications in placental pathology
• Up-to-date diagnostic criteria, grading, and relevance useful for more experienced placental pathologists
• Interactive weights and measurements tables

• Features new and updated details on emerging infectious diseases and the role of the autopsy practitioner in a pandemic setting
• Details new content on pathologies now seen at autopsy due to current drug therapies  (newer biologic therapies, etc.)
• Contains completely new topics detailing the following topics:
• Overview topics on morgue operation and maintenance, including technical aspects of the autopsy suite and autopsy histology
• Enhanced biosafety measures (including an emerging biohazard chapter) and autopsy suite engineering
• Emerging pathogens
• Toxicity/pathology associated with new drug therapies (CAR-T cancer therapies, checkpoint inhibitors, vaccine therapy, mRNA vaccine-related immune events, etc.)
• Relevant new cardiac/other medical devices not available when the previous edition published
• Distinct COVID-19 details (for deaths from COVID-19 as well as any contributing medical devices or vaccine complications)
• Focuses on helping pathologists in hospital settings determine the causes and mechanisms of death, but also provides value to forensic pathologists, private practice pathologists, and others involved in death investigation, such as coroners, medical examiners, law enforcement, as well as pathology residents
• Delivers detailed, up-to-date information for pathologists at all levels of experience far beyond filling out the autopsy report, with content on determining cause of death based on a defined set of examination methods and practices

• More than 140 topics grouped by specific organ transplant, including kidney, liver, heart, lung, intestine, and pancreas, as well as additional chapters on vascularized composite allotransplantation, posttransplant neoplastic disorders, and other important topics
• Each section features a consistent layout of topics, making specific information easy to find (for instance, each transplant section includes a group of allograft rejection topics); subsections consistently use such topics as surgical complications, recurrent diseases, drug toxicities, infections, etc.
• Includes completely new topics on transplant immunology that cover chronic viral infections in SOT and the immune response, immune manipulation and accommodation (an introduction to xenogeneic transplantation), and graft-vs.-host disease in SOT
• Contains new topics in the Pancreas Transplantation section on islet cell transplantation
• Features detailed information on xenotransplantation (the use of nonhuman tissue, cells, or organs in transplant) and specifically kidney xenograft—a topic in active research at this time and expected to lead to clinical trials in the coming years
• Is fully updated with current information from the 2022 update of the Banff classification, which published in 2023
• Covers advances in vascularized composite allograft (hands, face, uterus, phallus) transplantation
• Includes posttransplant histology updates for challenging biopsies with > 10 years after transplant

• Contains new and updated/expanded topics throughout, including COVID-19, mpox, Buruli ulcer (Mycobacterium ulcerans infection), eight new helminth topics, a detailed tick-identification topic, and additional new fungal topics that include culture plate, lactophenol blue, and cytology images for each
• Features an expanded introductory section with an updated biosafety topic (covering issues in frozen-section rooms, gross rooms, and at autopsy), as well as detailed discussions about powerful novel and emerging techniques (whole-slide imaging with AI, mass spectrometry imaging, and metagenomic next-generation sequencing)
• Features topics on most to least common infections of the central nervous system, head and neck, skin/soft tissue, as well as on the pulmonary, cardiac, gastrointestinal, genitourinary, and gynecologic systems; also includes best approach for diagnostic work-up
• Details the increasing use of molecular diagnostics in infectious disease pathology
• Addresses the challenges in maximizing diagnostic yield while avoiding misinterpretation of results that could lead to false positives

• Pediatric neoplasms content updated throughout, with revisions and additions to content, images, and references that eliminate out-of-date language, classification details, or diagnoses. In addition to a complete text/image overhaul, 10-12 new topics, including:
  • Intramuscular Fast-Flow Anomaly
  • Kaposiform Lymphangiomatosis
  • Lipofibromatosis
  • Receptor Tyrosine Kinase Rearranged Spindle Cell Tumor
  • Hamartomatous Polyps, Including Juvenile Polyps
  • Pediatric Hepatocellular Carcinoma
  • Renal Metanephric Tumors
  • Anaplastic Sarcoma
  • Nephrogenic Tumors, Including Wilms
  • Choriocarcinoma
• Provides diagnoses with clinically and diagnostically important information on typical and variant disease features for pediatric and general pathologists at all levels of experience
• Contains fully updated images and text, as well as a multitude of new chapters
• Features annotated images and full-color medical illustrations, as well updated literature references that provide additional details on each topic’s diagnoses

• Molecular oncology is a rapidly evolving field that has seen a tremendous amount of new information, including new molecular genetic data linked to either new targeted therapies or those that serve as diagnostic or prognostic indicators
• Features 8-10 new topics and substantial revisions to existing content that include updates from the WHO Classification of Hematolymphoid Tumors, 5th edition (2023 WHO Classification) as well as the 2022 International Consensus Classification (2022 ICC Classification). The authors provide guidance on selecting the right test(s) at the right time as well as comparisons of molecular testing methods (e.g., FISH vs. cytogenetics). The market currently lacks a definitive source for these recent changes, and these updates provide it.
• Incorporates the most recent data from the 2023 WHO Classification as well as the 2022 ICC Classification
• Includes current information for new actionable mutations and targeted therapies
• Describes updated and new NGS panels useful in the work-up of hematopoietic neoplasms and solid tumors
• Covers ultrasensitive molecular techniques for minimal residual disease detection and disease monitoring
• Discusses circulating cell-free DNA analysis for detection of resistance-associated mutations and disease monitoring, and provides usage details

• Updates on the classification of lower genital tract epithelial tumors, including new sections on cervical adenocarcinomas to match the latest WHO classification
• Integration of morphology and molecular information in endometrial adenocarcinomas
• New topics on emerging and newly recognized entities in the female genital tract, and on vascular tumors of the gynecologic tract
• Update of ancillary techniques and newly encountered pitfalls
• Up-to-date, comprehensive information covering the spectrum of nonneoplastic and neoplastic conditions of the female genital tract, including common and uncommon entities
• Curated, succinct, and easy-to-access content that includes updated differential diagnoses, as well as diagnostic pearls, with newly added references that back up the diagnostic details
• Updates throughout based on the 2020 WHO Classification of Tumours: Female Genital Tumours, including staging issues and measurement standards
• Details on advances in the molecular landscape of epithelial and mesenchymal tumors, which have prognostic and therapeutic implications and help delineate tumors in both categories
• Descriptions for new categories of tumors, newly refined descriptions, new subtypes, and diagnostic criteria

Includes details throughout to help pathologists identify IHC and molecular genetics as they pertain to soft tissue pathology

• Soft tissue pathology changes rapidly as new entities and variants are recognized and new molecular signatures for both new and existing entities become known. Soft Tissue Tumors’ text, images, and references reflect the most current knowledge available.
• Soft Tissue Tumors includes updates across multiple topics based on the most recent WHO Classification of Tumors: Soft Tissue and Bone Tumours (5th ed.)
• New topics cover the recently recognized EWSR1-SMAD3 fibroblastic tumor, plexiform myofibroblastoma, anastomosing hemangioma, myxoid pleomorphic liposarcoma, and more
• Updated contents and references cover new immunostains being used (mostly IHC surrogates for molecular testing)
• Provides comprehensive coverage of soft tissue pathology combined with accurate, concise clinicopathologic descriptions supported by thousands of high-quality photomicrographs, gross photographs, radiologic images, and medical illustrations

• Includes details from the WHO’s upcoming 5th Edition Classification of Tumours of Haematopoietic and Lymphoid Tissues expected this summer to ensure readers are up to date on new classification details, including new and renamed diagnostic entities, tumor classification changes and updates, and terminology changes and updates
• Also includes details from the upcoming International Consensus Classification of Hematolymphoid Neoplasms expected this summer, that will provide a parallel body of knowledge to the WHO Classification with potential new and renamed diagnostic entities, tumor classification changes and updates, and terminology changes and updates
• Features 10 new topics that cover:
  • SARS-CoV-2 infection features in blood and bone marrow
  • Myelodysplastic syndrome (MDS) mimics
  • Blood and bone marrow findings linked to targeted therapies
  • Blood and bone marrow findings linked to other medications
• Expansion and update of topics throughout covering the following and more:
  • T-cell neoplasms in blood and bone marrow
  • Intravascular large B-cell lymphoma in blood and bone marrow

Four new topics:

• Giant Cell Tubulitis With TBM Deposits
• Urine Leak
• Accommodation
• Diffuse Mesangial Sclerosis

The following topics are new or revised:

• Ameloblastoma, Unicystic; Basal Cell Adenocarcinoma; Basal Cell Adenoma; Ewing Sarcoma, Including Sinonasal Adamantinoma-Like; Germ Cell Tumors of Head and Neck; Hairy Polyp; Intercalated Duct Adenoma; Juvenile Trabecular Ossifying Fibroma; Lymphoepithelial Carcinoma, Larynx and Trachea; Middle Ear Papilloma; Psammomatoid Ossifying Fibroma; Rhabdomyosarcoma with TFCP2 Rearrangement

• Includes updates from the International Kidney and Monoclonal Gammopathy (IKMG) research group, the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for IgG4-related disease, and others
• Includes updates from several existing and upcoming classifications (Banff, IKMG, IgG4, etc.)
• Features two dozen new topics on a variety of timely topics, including COVID-19 nephropathies, xenografts, artificial intelligence (AI), digital pathology analysis, harmonized nephropathology terminology, newly identified types of amyloidosis, common artifacts and pitfalls on kidney biopsy, vaccination associated renal disease to crystal nephropathies, and much more
• Contains more than 4,300 images, including high-resolution photographs and histologic images, full-color medical illustrations, and more
• Includes updated genetic causes of nephrotic syndromes and antinephrin antibodies in podocytopathies (by the investigator that discovered it)
• Contains coverage of COVID-19 nephropathies and the newly identified variant IgG nephropathy, novel membranous autoantigens, AI in renal pathology, and kidney xenografts

• The following topics are new or revised
  • Ameloblastoma, Unicystic; Basal Cell Adenocarcinoma; Basal Cell Adenoma; Ewing Sarcoma, Including Sinonasal Adamantinoma-Like; Germ Cell Tumors of Head and Neck; Hairy Polyp; Intercalated Duct Adenoma; Juvenile Trabecular Ossifying Fibroma; Lymphoepithelial Carcinoma, Larynx and Trachea; Middle Ear Papilloma; Psammomatoid Ossifying Fibroma; Rhabdomyosarcoma With TFCP2 Rearrangement

• A new generation of updated cardiac devices requires pathologic evaluation. New topics evaluate this increasing volume of devices in both surgical and autopsy specimens
• Because pathologists require updates on the molecular panels used far more frequently for diagnosing cardiovascular disease, updates include new material from the currently expanding field of genetics on sudden cardiac death
• Covers issues regarding patients with COVID-19, who are experiencing a higher incidence of heart/vascular disease
• Includes details on the genetics that affect heart diseases—cardiomyopathy and aorta among them
• Covers amyloid treatment therapies that are now recommended
• Includes specifics on the reclassification of pulmonary arterial hypertension

• Lymph nodes and extranodal lymphomas is a systematic, easy-to-use, and in-depth reference that covers benign and malignant lesions of lymph nodes, as well as extranodal lymphomas. The lymphomas are largely designated using the latest WHO classification terminology. Clinical and histologic features, results of relevant ancillary studies, and a differential diagnosis for each entry are provided with thousands of images that include gross pathology photographs, relevant clinical images, photomicrographs of histology and special stains, flow cytometry histograms, radiologic images, and detailed medical illustrations.
• The pathology of lymph nodes and extranodal lymphomas is a rapidly changing field, and roughly 25% of this section reflects new information on the topic, including updates throughout and at least 6 new topics:
  • EBV(+) T- and NK-cell lymphoproliferative disorders of childhood
  • Erdheim-Chester disease
  • Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
  • Primary cutaneous acral CD8(+) lymphoma
  • Primary cutaneous CD4(+) small/medium T-cell lymphoproliferative disorder
  • Primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma

• New reporting terminology (serous fluid and effusions) and updates to existing reporting terminologies
• Details on new immunohistochemical and molecular coverage, including new immunostains and genomic targets, as well as ancillary molecular test coverage in the thyroid section
• Image updates throughout that illustrate the expanded use and growth of fine-needle aspiration for small biopsies (FNA-B)
• Details on reporting system updates for serous fluid classification and urinary cytology classification
• Updates on new immunohistochemistry and molecular tests
• Contents updated throughout (overall 20% new material)
• New topics on ancillary molecular tests specific to thyroid; prognostic/therapy-related immunomarkers in cell blocks and small biopsies
• ~ 8-10 new videos on such topics as the cytoprepratory process, cell transfer cell block, collodion bag cell block, and others
• The expanded use of FNA-B means small biopsy images will be added throughout, and many existing images will be updated to feature FNA-B
• ~ 20-25 brand-new illustrations
• Coverage of the new serous fluid classification system and the updated urinary cytology classification system, as well as new immunohistochemistry and molecular tests
• Updates on current and emerging reporting systems on pancreaticobiliary, salivary, breast, and soft tissue cytology

• Topics updated for Pox Virus Infections; Ebola, Marburg, and Other Hemorrhagic Fever Virus Infections; Parainfluenzia Viruses; and Coronavirus Disease 2019

• A new topic for:
  • Evaluation of sentinel lymph biopsies for gynecologic malignancies
  • Evaluation of margins from cervical resections
  • Use of artificial intelligence for intraoperative consultation
  • Use of ex vivo microscopy to evaluate gross specimens without the need for freezing tissue
  • A completely revised Safety Precautions topic with details on evaluating specimens from patients with COVID-19
  • o New discussion on STAS (spread through air spaces) for lung carcinoma evaluation
• All topics updated and new images and photographs added:
  • Designed to be the best resource possible during the limited amount of time a pathologist has to reach a crucial decision
  • Features updated images and text throughout to align with updated terminology and methods
  • Includes videos showing special techniques such as identifying radioactive seeds in breast biopsies, and evaluating lung margins containing staples by frozen section
  • Provides the latest information on the use of artificial intelligence and ex vivo microscopy for intraoperative evaluation

• Contains introductory chapters on electron microscopy, immunofluorescence, the cell, the basic organization of tissues, and immunohistochemistry and histochemistry
• 50-65% of the topics contain new images showing the most common abnormal findings to provide comparison and contrast with normal histology

• Provides details on more than 270 of the most commonly encountered nonneoplastic entities in pediatric pathology. Covers every organ system, focusing on reactive, infectious, congenital, and genetic conditions.
• Features a thoroughly updated Molecular Factors Index, which cross-references gene names and locations with chapter content specifics
• Contains more than 2,400 images and illustrations
• Employs consistently templated chapters and bulleted content for quick, expert reference at the point of care
• New molecular discoveries, such as the DICER1 mutation, which have changed the diagnostic process for nonneoplastic pediatrics, especially in the area of autoimmune diseases
• Changes and expansions to multiple classification systems (e.g., WHO, Banff, ISSVA, etc.), including a new scoring system for autoimmune hepatitis and updated disease entities for neonatal hepatitis and vascular malformations
• Updates in immunologic disorders such as eosinophilic esophagitis and gastroenteritis
• The new scoring system for pediatric autoimmune hepatitis
• Contains 8 to 12 new topics on the following topics:
  • COVID-19
  • Tumoral calcinosis
  • Multiple skeletal dysplasia
  • Skeletal muscle
  • Collagenous gastritis and colitis
  • Adenovirus appendicitis
  • Intestinal pseudoobstruction
  • Disorders of sexual development
  • Kikuchi disease

• Updates based on new guidelines and recommendations; new references

• New reporting terminology (serous fluid and effusions) and updates to existing reporting terminologies
• Details on new immunohistochemical and molecular coverage, including new immunostains and genomic targets, as well as ancillary molecular test coverage in the thyroid section
• Image updates throughout that illustrate the expanded use and growth of fine-needle aspiration for small biopsies (FNA-B)
• Details on reporting system updates for serous fluid classification and urinary cytology classification
• Updates on new immunohistochemistry and molecular tests
• New topics on ancillary molecular tests specific to thyroid; prognostic/therapy-related immunomarkers in cell blocks and small biopsies
• ~ 8-10 new videos on such topics as the cytoprepratory process, cell transfer cell block, collodion bag cell block, and others
• The expanded use of FNA-B means small biopsy images will be added throughout, and many existing images will be updated to feature FNA-B
• ~ 20-25 brand-new illustrations
• Coverage of the new serous fluid classification system and the updated urinary cytology classification system, as well as new immunohistochemistry and molecular tests
• Updates on current and emerging reporting systems on pancreaticobiliary, salivary, breast, and soft tissue cytology

• Endocrine updates address characteristics of more than 150 diagnoses, and most entities are detailed with medical illustrations, micrographs, gross photographs, and other image types
• Contributions from renowned pathologists ensure that common/classic endocrine diagnoses, as well as newly recognized diseases and unusual cases, are well covered
• Topics are consistently templated with bulleted content, including nearly 2,000 images for efficient, expert reference at the point of care
• Offers a wealth of new information based on recently recognized and discovered endocrine diseases, as well as tumor types with important implications for patient care. This includes:
  • Recently described thyroid tumors now associated with DICER1 gene mutations
  • Correlation of newly characterized genetic abnormalities in endocrine tumors associated with responses to targeted therapies, as kinase fusion-related thyroid carcinomas and NTRK-rearranged thyroid carcinomas are now recognized as targetable tumors with correlation between genotype and tumor behavior and evolving resistance mechanisms against kinase inhibitors
  • Newly recognized syndromes, such as multiple endocrine neoplasia type 4 and type 5, glucagon cell hyperplasia and neoplasia, and others
  • Updates, as per the latest World Health Organization (WHO) Classification of Tumors of Endocrine Organs, expected to be released by the end of 2021

• Topics updated based on new guidelines and recommendations, and including references

• All 110 topics underwent updates to both topic content and to the topic references
• Over 10 new tables and figures added
• Greater than 50 topics not only updated but also expanded with additional details added to content, including updates related to FDA regulations for infectious disease testing, COVID-19 convalescent plasma, ASFA Guidelines, low titer group O whole blood, Cellular Therapy, and many more!

• The perception of normal histology has continued to expand and improve since the previous update of this section. The identification of new variations on what is considered normal histology can cause diagnostic confusion, and advances in immunohistochemistry continuously expand the spectrum of how normal tissues express. Bolstered with updates throughout that were not available in 2017, as well as multiple new topics and images. This update provides clear, concise information on the normal histology of each organ system for expert evaluation and diagnosis at the time of procedure. Practicing pathologists, pathologists in training, medical students, and histology students in any setting will find the normal histology section an invaluable, up-to-date resource in this rapidly evolving field
• More than half this section’s chapters feature new images illustrating the most common abnormal findings to compare and contrast with normal histology
• Contains introductory topics on electron microscopy, immunofluorescence, the cell, the basic organization of tissues, and immunohistochemistry and histochemistry
• 50-65% of the book’s topics contain new images showing the most common abnormal findings to provide comparison and contrast with normal histology

• 49 topics updated based on new guidelines with new references

• 31 remaining documents updated, constituting the final portion of a complete revision of endoscopic correlations

• 25 topics updated based on new guidelines with new references

• Four new and updated topics:
  • Monkeypox and Other Pox Virus Infections
  • Ebola, Marburg, and Other Hemorrhagic Fever Virus Infections
  • Coronavirus Disease 2019 (COVID-19)
  • Neisseria and Moraxella Species Infections

• Contains the newest staging information released in the AJCC Cancer Staging Manual, 8th Edition. There is focus on practical issues pertaining to pathologic staging in resection specimens.
• Provides genitourinary pathologists with relevant details and updates from the multiomic (or whole genome) approach, which combines information from multiple sources (“omic groups”) to identify important pathways and discovery of new genes involved in human cancers as applicable to their clinical practice.
• Delivers one-stop diagnostic compendium to enable accurate, complete surgical pathology reports. Will employ contemporary ancillary studies and provide expert reference at the point of care for pathologists. Will also serve as a training resource for pathology fellows and residents.
• Covers the latest changes in precision medicine and continuous advances in oncology research, including the discovery of new urologic cancer biomarkers

• Extensive updates to the clinical pathology sections of ExpertPath including:
  • 53 updated topics in Medical Microbiology
  • 42 updated topics in Clinical Chemistry
  • 21 updated topics in Hematology, Hemostasis, and Thrombosis
  • 2 updated topics in Transfusion Medicine

• 72 topics updated including new images
• New topics written for:
  • Arteriovenous Malformation
  • Angiodysplasia
  • Checkpoint Inhibitor Therapy
  • Olmesartan and Related Compounds
  • Medications that Induce Mitotic Arrest
  • Ion Exchange Resins and Sequestrants

• Completely revised with major updates on sinonasal tract, salivary gland, and odontogenic tumors, including pertinent immunohistochemistry profiles and discriminating molecular findings, including essential material from recent AJCC 8e and WHO 5e updates
• Covers all topics, with emphasis on the diagnoses encountered in daily practice (such as infections and inflammatory/reactive issues)
• Specific issues regarding oropharyngeal squamous cell carcinoma and its correct classification and staging, especially as they relate to the AJCC 8e and the 2022 WHO 5e
• Topics related to the recent significant reclassification of salivary gland tumors:
  • High-grade transformation is recognized instead of dedifferentiation
  • Polymorphous adenocarcinoma subsumes polymorphous low-grade adenocarcinoma, cribriform adenocarcinoma of tongue and minor salivary glands, and papillary adenocarcinoma
  • Intercalated duct carcinoma, sclerosing polycystic adenoma, striated adenoma, and intercalated duct adenoma are recognized as a tumor unique from salivary duct carcinoma
  • Ciliated variants of mucoepidermoid carcinoma are now recognized
  • Unique molecular signatures are seen in specific variants of salivary gland tumors
• Odontogenic tumor information, including molecular findings as well as specific variants or subtypes of major categories
• Updated and expanded immunohistochemistry profiles to allow for more robust and reproducible classification

• Thoracic pathology has changed demonstrably, with the importance of next-generation sequencing and the explosion of molecular genetic information bringing major changes to the management of patients with thoracic disease. The thoracic updates give anatomic and surgical pathologists, pathology residents, and fellows in training a thoroughly updated, comprehensive resource to build the most accurate diagnoses for thoracic pathology issues during their routine sign-out of cases.
• Features an extensive content overhaul with updates to the most current information for all lung, pleura, and mediastinum entities and 30+ topics having been thoroughly revised
• Includes a substantial number of new, higher-quality images and updates to existing ones that more effectively illustrate important points and recent developments for all entities
• Includes updated criteria, terminology, and classifications for a wide range of tumors from the 2021 WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, reflecting changes to currently used terminologies for adenocarcinoma, squamous cell carcinoma, neuroendocrine tumors, mesothelioma, soft tissue tumors, benign tumors, and more.
• Contains a new “Molecular Pathology” section for all entities in chapters with new information on the genetic underpinnings of diseases. Genetic mutation types identified with each tumor will be specified, along with next-generation sequencing studies and other techniques and how the specific genetic alterations are used to differentiate disease and aid in diagnosis.
• Multiple consensus clinical practice guidelines for thoracic disease diagnosis from 2018 forward are now included, including those for molecular genetic testing and predictive biomarker testing from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

• New chapter, and updates to existing chapters, are included to incorporate details regarding several types of tumors that have been reclassified due to molecular driver information that has come to light since the publication of the WHO 2016. For example, new chapters on pediatric glial and glioneuronal tumors are included since new evidence proves these tumors don’t belong in the formerly used generic IDH-wildtype group (relating to WHO grade IV status)
• New diagnostic clarifications are included in several chapters since it has been recognized subsequent to WHO CNS 2016 that a group of circumscribed tumors did not necessarily automatically deserve WHO Grade IV status
• Addition of a more detailed molecular diagnostics topic with a section on methylation profiling, which has become unavoidable as a method of tumor classification.

• 36 updated topics
  • New and revised clinical and histological images
  • Updated text and reference information

• 28 updated topics under uterine corpus and uterine cervix
  • Updated classification and images

• 15 updated topics with new references and histopathologic images

• Enables identification of nonneoplastic lesions
• Organized into major histological reaction patterns and/or disease categories
• Includes clinical images for all 250+ nonneoplastic entities so that practicing and in-training pathologists gain a better understanding of the clinical and histopathological appearance of nonneoplastic lesions and, more importantly, their major histological and clinical differential diagnoses
• Includes approximately 4,150 quality clinical and histological images to further assist in the creation of the most accurate diagnosis for patients

Features updates to important content areas, including the following:

• New topics on COVID-related rashes, measles, and hair-shaft disorders, among others
• New information on unknown and previously unknown side effects regarding long-term immunosuppressed patients
• New details on infectious processes for diseases
• Updates on drug rashes as new/additional drugs are being used in treatment
• Updated images throughout for new cases and replacement of older images
• New information on rare infections and clinical identification of rare diseases
• Additional diagnosis details on uncommon but not rare disorders, including hair-shaft disorders

• The update addresses recent advances in molecular pathology—particularly new diagnostic, immunohistochemical, molecular, and genetic techniques used for diagnosis, as well as updated reportable staging details for several new diagnoses and identification of newly recognized tumors
• Diagnosis of uncommon tumors unique to the skin along with proliferations more commonly seen in other organ systems that also involve the skin can be challenging for general pathologists, dermatologists, and even dermatopathologists. DP3: Derm Neo is a one-stop reference that helps accelerate accurate diagnoses.
• Descriptions of more than 250+ cutaneous neoplasms are bolstered by clinical correlates that add real depth and value for its audience. Most topics have clinical photographs, and all contain sections with relevant clinical information, including epidemiology, presentation, treatment, and prognosis.
• Current CAP-approved staging protocols reference for tumors, including melanoma and squamous cell carcinoma
• Carefully annotated images focused on histopathological features to help make a wide range of diseases more easily differentiated
• Detailed, concise, and bulleted chapters deliver critical diagnostic information such as definitions, epidemiology, clinical presentation, macro- and microscopic features, differential diagnoses, and pathologic interpretation pearls
• Since the previous edition (2016), molecular pathology studies have shown altered components in various pathways in different cutaneous tumors, which are updated in DP3: Derm Neo
• New information and details based on the 2018 WHO-EORTC update, the consensus classification for diagnosis and classification of primary cutaneous lymphomas
• Updated staging details for melanoma, cutaneous lymphoma, and several additional tumors are also included
• Includes approximately 3,700 quality clinical and histological images to further in assist in the most accurate diagnosis for patients

• Features material based on the WHO's 2019 updates, including new terminology, and grading of neuroendocrine tumors and neuroendocrine carcinomas. These are changes that could directly impact treatment.
• The WHO recently defined many new variantsof hepatocellular carcinoma, each with distinct molecular alterations, that pathologists may not be aware of. Pathologists may not know which subtypes are clinically relevant to report.
• Many novel immunohistochemical markers or other ancillary techniques have become available—BAP1, INSM1, Rb, albumin in situ hybridization, etc.—that are playing an increasingly critical role in improving diagnoses, but are still not widely incorporated into practice because of limited awareness. The 3rd edition of DP: Hepatobiliary and Pancreas will include these topics.
• Incorporates recent information from the WHO on characteristic molecular alterations in hepatocellular adenoma, cholangiocarcinoma, and others that play a role in the diagnosis and treatment of these tumors. Knowledge of this updated information remains low among many practicing pathologists.
• Features updated and new chapters and images to incorporate changes based on details in the new classifications
• Contains updates from the AJCC's 8^th Edition Cancer Staging Manual, including terminology, as well as updated grading and staging of hepatic and pancreaticobiliary tumors
• Will feature new images and updated text throughout to include new details about the genesis and activity of tumors in the liver, pancreas, and biliary systems
• Incorporates recently described immunohistochemical and molecular assays that help in the diagnosis
• Includes approximately 1,600 quality clinical and histological images to further in assist in the most accurate diagnosis for patients

• 149 documents reviewed and updated to include new gene fusion notation

• 13 updated documents comprising approximately 120 new and revised clinical and histological images

• One new topic, Clinical Practice Guidelines for Initial Work-Up of Acute Leukemia

• Complete revision to the Bone Section of ExpertPath
  • All documents have been reviewed and revised, including several new documents
• New chapters include the following:
  • Growth and Development
  • Radiologic Approach to Bone Tumors
  • Synovial Tumors
• Common Non-Neoplastic Orthopedic Specimens section to include the following chapters:
  • Osteoarthrosis
  • Osteonecrosis
  • Pathology of intervertebral discs and menisci
  • Non-infectious inflammatory arthritis
  • Crystal deposition diseases
  • Common metabolic disorders
• Includes common nonneoplastic lesions encountered in daily practice

• Updates to Antibrush Border Autoantibody Tubulointerstitial Nephritis, Hepatitis B Virus, Intravascular Large B-Cell Lymphoma, Introduction to Diseases with Immunoglobulin Deposits, Introduction to Renal Pathology, Lithium-Induced Renal Disease, Paracoccidioidomycosis, Polyomavirus Detection in Tissue, Renal Vein Thrombosis, and Retinal Vasculopathy and Cerebral Leukodystrophy

• Updates to Glomangiopericytoma, Nose and Paranasal Sinuses, NUT Carcinoma, Secretory Carcinoma, and Salivary Gland

• Update to Benign Mucinous Tumors

• Updates to new tumor staging data in the American Joint Committee on Cancer (AJCC) 8th Edition
• Includes a range of new breast pathology details to help pathologists identify, diagnose, and manage disease
• Contains new documents, including
  • Patterns in mucinous and cribriform lesions
  • Patterns in small glandular proliferations
  • Immunotherapy markers and neoadjuvant reporting
  • Updated HER2 guidelines for reporting
  • Solid Papillary Carcinoma
  • Acinic Cell Carcinomas
  • Intraoperative consultations contents related to breast, including videos of interactive seed localization
  • And much more; take a stroll through the breast content area and see for yourself!

• 16 documents updated to reflect new information related to familial cancer syndromes

• 12 updates to head and neck documents to reflect the latest changes in the literature